BOLT
Bolt Biotherapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.90
+0.13%Margins
Gross margin
95.7%
EBITDA margin
-591.9%
EBIT margin
-623.0%
Net margin
-611.5%
FCF margin
-671.0%
-227.4%
Return on equity
-71.2%
Return on assets
-85.5%
Return on invested capital
0.11x
Asset turnover
-$31.5M
Cash from operations
$9.14
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026